Editorial
|
|
|
|
|
Naming drugs with international nonproprietary names
|
|
|
|
New Products
|
|
|
|
|
New indications, but not robust evidence
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The only vaccine against some serogroup B meningococci
|
|
|
|
|
|
|
|
|
|
|
|
Too soon to reach conclusions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Just a teriparatide me-too
|
|
|
|
|
|
|
|
|
|
Cervical cancer: just another vaccine
|
|
|
|
|
|
|
|
|
|
Used patches should be handled with care
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No pain justifies the use of a cox-2 inhibitor
|
|
|
|
|
|
|
|
|
|
Keep using fluorouracil-based chemotherapy
|
|
|
|
|
|
|
|
|
|
Oral route for some patients
|
|
|
|
|
|
|
|
|
|
No role for meprobamate in any indication
|
|
|
|
|
|
|
|
|
|
Better to continue to use bosentan
|
|
|
|
|
|
|
|
|
|
After multiple antiretroviral treatment failure: another option
|
|
|
|
|
|
|
|
|
|
A poor risk-benefit balance in type II mucopolysaccharidosis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Try other single-agent treatments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peppermint seems effective
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|